{
    "clinical_study": {
        "@rank": "163259", 
        "acronym": "IMPERIUM", 
        "arm_group": [
            {
                "arm_group_label": "Strategy A (Glucose-Dependent)", 
                "arm_group_type": "Experimental", 
                "description": "Participants may receive oral and injectable therapies (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID).  Choice of therapy is based on investigator's discretion. Treatment used in label.  Dose titrated by treatment algorithm.  Treatment may last up to 72 weeks."
            }, 
            {
                "arm_group_label": "Strategy B (Reference)", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy.  Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine.  Choice of therapy is based on investigator's discretion.  Treatment used in label.  Dose titrated by treatment algorithm.  Treatment may last up to 72 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to compare the benefits and risks associated with the use\n      of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.\n      One strategy is based on the use of oral and injectable medications that only reduce blood\n      sugar (glucose) when it is high.  The other strategy is based on non-glucose dependent\n      agents.  The trial will last up to 72 weeks for each participant."
        }, 
        "brief_title": "A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have T2DM based on a history and clinical impression that is consistent with the\n             World Health Organization [WHO] Classification of Diabetes\n\n          -  Have a Clinical Frailty Scale (CFS) score of 4 or above or Total Illness Burden Index\n             (TIBI) score of 5 or above as assessed at screening\n\n          -  Have an A1c >7.3% and <10.9% at study entry and are not achieving desired glycemic\n             control as evidenced by A1c measurement at least 0.4% higher than individualized\n             treatment target set at screening.\n\n          -  Have been treated for at least 3 months prior to the study entry with any of the\n             following treatment options:\n\n               -  Diet/exercise only (only if they have known contraindications to metformin\n                  treatment)\n\n               -  Any dose of sulfonylurea\n\n               -  Effective or maximally-tolerated doses of metformin, dipeptidyl-peptidase-4\n                  (DPP-4) inhibitor, thiazolidinedione, or acarbose used in monotherapy or in dual\n                  combination. The following doses are considered to be effective:\n\n                    -  at least 1500 mg of metformin per day\n\n                    -  At least 30 mg of pioglitazone per day\n\n                    -  At least 4 mg of rosiglitazone per day\n\n                    -  At least 75 mg of acarbose per day\n\n                    -  Any marketed dose of DPP-4 inhibitor\n\n        Exclusion Criteria:\n\n          -  Are currently enrolled in a clinical trial involving an investigational product or\n             nonapproved use of a drug or device (other than the investigational product used in\n             this study), or concurrently enrolled in any other type of medical research judged\n             not to be scientifically or medically compatible with this study\n\n          -  Have participated, within the last 60 days in a clinical trial involving an\n             investigational product other than the investigational product used in this study. If\n             the previous investigational product has a long half-life, 3 months or 5 half-lives\n             (whichever is longer) should have passed\n\n          -  Have previously completed or withdrawn from this study. This exclusion criterion does\n             not apply to participants who are rescreened prior to randomization\n\n          -  At study entry, have contraindications to sulfonylurea, insulin, or GLP-1 RA\n\n          -  Have a history of pancreatitis, a personal or family history of medullary thyroid\n             carcinoma, or have Multiple Endocrine Neoplasia syndrome type 2\n\n          -  Have taken any injectable glucose-lowering agent, miglitol, meglitinide,\n             Sodium/Glucose cotransporter-2 inhibitor, or other antihyperglycemia treatment that\n             is not listed in the fourth inclusion criterion for more than 10 days within 3 months\n             prior to the study entry\n\n          -  In the opinion of investigator should have an individualized A1c target set at 8% or\n             higher\n\n          -  Have a body mass index (BMI) greater than 45 kg/m^2\n\n          -  Have had more than 1 episode of severe hypoglycemia within 24 weeks prior to the\n             study\n\n          -  Have cardiac disease with functional status that is Class III or IV according to the\n             New York Heart Association Cardiac Disease Classification\n\n          -  Have an estimated glomerular filtration rate (eGFR) <30 milliliter/minute/1.73 m^2\n             (mL/min/1.73 m^2) or advance renal disease including history of renal transplantation\n             or currently receiving renal dialysis\n\n          -  Have obvious clinical signs or symptoms or laboratory evidence of liver disease\n             (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 2.5 times the\n             upper limit of the reference range)\n\n          -  Receive current therapy for a malignancy, other than basal-cell or squamous-cell skin\n             cancer\n\n          -  Received systemic glucocorticoids within the 3 months prior to entry for more than 14\n             consecutive days\n\n          -  Have any other condition that precludes the participant from following and completing\n             the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "880", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02072096", 
            "org_study_id": "14842", 
            "secondary_id": [
                "F3Z-MC-IOQL", 
                "2013\u2010001473\u201024"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Strategy B (Reference)", 
                "description": "Administered orally", 
                "intervention_name": "Glimepiride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Strategy A (Glucose-Dependent)", 
                    "Strategy B (Reference)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Strategy A (Glucose-Dependent)", 
                    "Strategy B (Reference)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Pioglitazone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Strategy A (Glucose-Dependent)", 
                    "Strategy B (Reference)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Acarbose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Strategy A (Glucose-Dependent)", 
                    "Strategy B (Reference)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Linagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Strategy A (Glucose-Dependent)", 
                    "Strategy B (Reference)"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Strategy A (Glucose-Dependent)", 
                "description": "Administered orally", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Strategy B (Reference)", 
                "description": "Administered subcutaneously (SQ)", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Strategy A (Glucose-Dependent)", 
                "description": "Administered SQ", 
                "intervention_name": "Exenatide once weekly (QW)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Strategy A (Glucose-Dependent)", 
                "description": "Administered SQ", 
                "intervention_name": "Exenatide twice daily (BID)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Pioglitazone", 
                "Exenatide", 
                "Glargine", 
                "Sitagliptin", 
                "BI 1356", 
                "Insulin", 
                "Metformin", 
                "Acarbose", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Concord", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94520"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33175"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34652"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Suwanee", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30024"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Idaho Falls", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Des Moines", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "50314"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Topeka", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66606"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55416"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "St Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashua", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03063"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Myrtle Beach", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29572"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79925"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "99202"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5026"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Stefan Ob Stainz", 
                        "country": "Austria", 
                        "zip": "A-8511"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A 1210"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Aschaffenburg", 
                        "country": "Germany", 
                        "zip": "63739"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10409"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dortmund", 
                        "country": "Germany", 
                        "zip": "44137"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22607"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany", 
                        "zip": "55116"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "48145"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Neuwied", 
                        "country": "Germany", 
                        "zip": "56564"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Stuttgart", 
                        "country": "Germany", 
                        "zip": "70378"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Manati", 
                        "country": "Puerto Rico", 
                        "zip": "00674"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00917-3104"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Salford", 
                        "country": "United Kingdom", 
                        "state": "Manchester", 
                        "zip": "M6 8HD"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "DD1 9SY"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "state": "South Yorkshire", 
                        "zip": "S5 7AU"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ipswich", 
                        "country": "United Kingdom", 
                        "state": "Suffolk", 
                        "zip": "IP4 5PD"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M41 5SL"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Germany", 
                "Puerto Rico", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)", 
        "other_outcome": [
            {
                "measure": "Change from Baseline in Adult Low Blood Sugar Survey (ALBSS) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 48 weeks, 72 weeks"
            }, 
            {
                "measure": "Change from Baseline in European Quality of Life-5 Dimensions 5 Levels (EQ-5D-5L) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 48 weeks, 72 weeks"
            }, 
            {
                "measure": "Change from Baseline in Mini-mental State Examination (MMSE) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 48 weeks, 72 weeks"
            }
        ], 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Federal Office for Safety in Health Care", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (A1c) Targets Without Clinically Significant Hypoglycemia", 
            "safety_issue": "No", 
            "time_frame": "Baseline through 72 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02072096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants Requiring Alternative Treatment Due to Glycemic Failure of First Line Injectable Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 72 weeks"
            }, 
            {
                "measure": "Incidence of Total Hypoglycemia and Other Categories of Hypoglycemia", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through 72 weeks"
            }, 
            {
                "measure": "Change from Baseline of Urinary Albumin to Creatinine Ratio", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through 72 weeks"
            }, 
            {
                "measure": "Change from Baseline in Body Mass Index (BMI)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through 72 weeks"
            }, 
            {
                "measure": "Change from Baseline of Estimated Glomerular Filtration Rate (eGFR)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through 72 weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}